Lisata Therapeutics’ (LSTA) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA – Free Report) in a research report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. Lisata Therapeutics Price Performance Lisata Therapeutics stock opened at $2.95 on Thursday. The stock’s fifty day moving average price […]
More Stories
Patton Albertson Miller Group LLC Has $1.54 Million Position in SPDR Blackstone Senior Loan ETF (NYSEARCA:SRLN)
Patton Albertson Miller Group LLC cut its holdings in shares of SPDR Blackstone Senior Loan ETF (NYSEARCA:SRLN – Free Report)...
PAR Technology (NYSE:PAR) Receives Buy Rating from Needham & Company LLC
PAR Technology (NYSE:PAR – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company...
Cerity Partners LLC Has $345.22 Million Position in Broadcom Inc. (NASDAQ:AVGO)
Cerity Partners LLC increased its stake in shares of Broadcom Inc. (NASDAQ:AVGO – Free Report) by 1,047.7% in the third...
Alaska Air Group (NYSE:ALK) Receives Buy Rating from UBS Group
Alaska Air Group (NYSE:ALK – Get Free Report)‘s stock had its “buy” rating reissued by analysts at UBS Group in...
Plus Therapeutics’ (PSTV) Buy Rating Reaffirmed at HC Wainwright
Plus Therapeutics (NASDAQ:PSTV – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a...
AMMO Receives Nasdaq Deficiency Notice for Delayed 10-Q Filing
On November 20, 2024, AMMO, Inc. (NASDAQ: POWW) acknowledged receipt of a deficiency notification from The Nasdaq Stock Market LLC,...